S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Freshworks gets juiced on its AI customer engagement platform
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
3 tech outperformers adored by analysts
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
High short interest stocks: this popular trend is re-emerging
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Freshworks gets juiced on its AI customer engagement platform
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
3 tech outperformers adored by analysts
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
High short interest stocks: this popular trend is re-emerging
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Freshworks gets juiced on its AI customer engagement platform
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
3 tech outperformers adored by analysts
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
High short interest stocks: this popular trend is re-emerging
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Freshworks gets juiced on its AI customer engagement platform
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
3 tech outperformers adored by analysts
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
High short interest stocks: this popular trend is re-emerging
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months

22nd Century Group (XXII) Stock Price, News & Analysis

$0.23
-0.01 (-4.13%)
(As of 12/8/2023 08:58 PM ET)
Compare
Today's Range
$0.21
$0.23
50-Day Range
$0.21
$0.88
52-Week Range
$0.20
$18.98
Volume
1.06 million shs
Average Volume
688,991 shs
Market Capitalization
$7.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.17

22nd Century Group MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
8,233.3% Upside
$19.17 Price Target
Short Interest
Healthy
4.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of 22nd Century Group in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.30) to ($0.95) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars


XXII stock logo

About 22nd Century Group Stock (NASDAQ:XXII)

22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies. The company has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.

XXII Stock Price History

XXII Stock News Headlines

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
22nd Century Group, Inc. (NASDAQ:XXII) Short Interest Update
22nd Century Appoints Larry Firestone As Chairman, CEO
22nd Century Appoints Larry Firestone as Chairman and CEO
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
This Stock Is Not Having Its Moment of the 'Century'
22nd Century loses $73M in 3rd quarter
22nd Century Group (XXII) Reduces Debt by $8.1 Million
See More Headlines
Receive XXII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 22nd Century Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/14/2024

Industry, Sector and Symbol

Industry
Cigarettes
Sub-Industry
Cannabis
Current Symbol
NASDAQ:XXII
Employees
198
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.17
High Stock Price Target
$45.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+8,233.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-59,800,000.00
Net Margins
-167.13%
Pretax Margin
-164.47%

Debt

Sales & Book Value

Annual Sales
$62.11 million
Book Value
$6.68 per share

Miscellaneous

Free Float
30,693,000
Market Cap
$7.10 million
Optionable
Optionable
Beta
1.58
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives















XXII Stock Analysis - Frequently Asked Questions

Should I buy or sell 22nd Century Group stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 22nd Century Group in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" XXII shares.
View XXII analyst ratings
or view top-rated stocks.

What is 22nd Century Group's stock price target for 2024?

4 Wall Street research analysts have issued 1 year target prices for 22nd Century Group's shares. Their XXII share price targets range from $5.00 to $45.00. On average, they anticipate the company's stock price to reach $19.17 in the next twelve months. This suggests a possible upside of 8,233.3% from the stock's current price.
View analysts price targets for XXII
or view top-rated stocks among Wall Street analysts.

How have XXII shares performed in 2023?

22nd Century Group's stock was trading at $13.8075 at the start of the year. Since then, XXII shares have decreased by 98.3% and is now trading at $0.23.
View the best growth stocks for 2023 here
.

Are investors shorting 22nd Century Group?

22nd Century Group saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,490,000 shares, a drop of 19.5% from the October 31st total of 1,850,000 shares. Based on an average daily volume of 717,200 shares, the short-interest ratio is currently 2.1 days. Currently, 4.9% of the company's shares are short sold.
View 22nd Century Group's Short Interest
.

When is 22nd Century Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our XXII earnings forecast
.

How were 22nd Century Group's earnings last quarter?

22nd Century Group, Inc. (NASDAQ:XXII) posted its quarterly earnings data on Monday, November, 6th. The biotechnology company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.13. The biotechnology company earned $17.81 million during the quarter, compared to analyst estimates of $20.06 million. 22nd Century Group had a negative net margin of 167.13% and a negative trailing twelve-month return on equity of 121.41%.

What ETF holds 22nd Century Group's stock ?

ETFMG Alternative Harvest ETF holds 55,201 shares of XXII stock, representing 0.08% of its portfolio.

When did 22nd Century Group's stock split?

22nd Century Group's stock reverse split on the morning of Wednesday, July 5th 2023. The 1-15 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of 22nd Century Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 22nd Century Group investors own include Aurora Cannabis (ACB), Alteryx (AYX), Auxly Cannabis Group (CBWTF), Charlotte's Web (CWBHF), Enphase Energy (ENPH), Inseego (INSG), Luckin Coffee (LKNCY), MediPharm Labs (MEDIF) and MercadoLibre (MELI).

Who are 22nd Century Group's major shareholders?

22nd Century Group's stock is owned by many different retail and institutional investors. Top institutional investors include HighTower Advisors LLC (0.37%), Mercer Global Advisors Inc. ADV (0.24%), Walleye Capital LLC (0.00%), TRUE Private Wealth Advisors (0.10%), Cutler Group LLC CA (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Clifford B Fleet, James A Mish, John Franzino, Michael Zercher and Roger D O'brien.
View institutional ownership trends
.

How do I buy shares of 22nd Century Group?

Shares of XXII stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:XXII) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -